Search results
Pharma Stock Roundup: FDA Nod to MRK's New Jab & Expanded Use of ABBV & AZN Drugs
Zacks via Yahoo Finance· 4 days agoFDA approves Merck's (MRK) 21-valent pneumococcal conjugate vaccine, Capvaxive and the expanded use...
States struggle to help patients navigate insurance hurdle known as ‘step therapy’
North Dakota Monitor via Yahoo News· 2 days agoCassidy Yermal, 32, began experiencing debilitating migraines when she was 17 years old. As a...
Did Teva Pharmaceutical Industries Limited (TEVA)’s “Pivot to Growth” Strategy Help It Get a...
Insider Monkey via Yahoo Finance· 3 days agoWe recently compiled a list of the 10 Best Robinhood Stocks Under $20. In this article, we are going...
Walking Helps Guard Against Recurrent Low Back Pain
Medscape· 5 days agoRegular walking can help prevent recurrent episodes of low back pain, a new study suggests. Among adults who recently recovered from an episode of low...
AbbVie stock price forecast: $200 on the cards? | Invezz
Invezz· 5 days agoThis approval is a significant milestone, making Skyrizi now available for four different conditions in the U.S., including psoriatic arthritis, plaque ...
A New Psychotherapeutic 'Gold Standard' for Chronic Pain?
Medscape· 6 days agoA single course of treatment with emotional awareness and expression therapy (EAET) was associated...
Amgen Inc. (NASDAQ:AMGN) Stake Lowered by First PREMIER Bank
ETF DAILY NEWS· 21 hours agoFirst PREMIER Bank reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.1% during the 1st quarter, according to the company in its most recent filing with the Securities ...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the...
Morningstar· 5 days agoJohnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA ...
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio...
Morningstar· 7 days agoApproval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND2Data showed that clinical remission,
J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease
Zacks· 4 days agoJ&J (JNJ) seeks label expansion for Tremfya for treating moderately to severely active Crohn's disease. This marks the second sBLA filing for Tremfya in three months.